登录 | 注册    微信公众号  
搜索

FOLR2信息

英文名称:Folate receptor beta
中文名称:叶酸受体β
靶点别称:FOLR1,FRbeta,Folate Receptor Alpha,FBP,Placental folate-binding protein,Folate receptor, fetal/placental,FOLR2,Folate receptor beta,Folate Receptor 2 (Fetal),Folate-Binding Protein, Fetal/Placental,BETA-HFR,FBP/PL-1,FR-Beta,FR-P3,Folate Receptor 2,FRβ
上市药物数量:0
临床药物数量:3
最高研发阶段:临床三期

FOLR2 分子别名

FOLR2,BETA-HFR,FBP,PL-1,FR-BETA,FR-P3,FBP

FOLR2 分子背景

Folate receptor beta is also known as Folate receptor 2, FBP, FOLR2, BETA-HFR, FBP/PL-1, FR-BETA, FR-P3, and is a member of the folate receptor (FOLR) family. and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. This protein has a 68% and 79% sequence homology with the FOLR1 and FOLR3 proteins, respectively. The FOLR2 protein was originally thought to exist only in placenta, but is also detected in spleen, bone marrow, and thymus. FOLR2 is predominantly expressed in placenta, cells of the neutrophilic lineage, and some CD34+ hematopoietic progenitor cells. It is upregulated on myeloid leukemias, head and neck squamous cell carcinomas, and several nonepithelial cancers. It is also upregulated on macrophages and monocytes at chronic inflammatory sites including rheumatoid arthritis synovium and glioblastoma. FOLR2 is a marker for macrophages generated in the presence of M-CSF, but not GM-CSF. Its expression correlates with increased folate uptake ability. Folate conjugates of therapeutic drugs are a potential immunotherapy tool to target tumor-associated macrophages.

FOLR2 前沿进展

FOLR2临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Vintafolide EC-145; MK-8109 临床二期 诺华制药 卵巢癌, 实体瘤, 肺腺癌, 乳腺癌, 子宫内膜癌, 非小细胞肺癌 详情
Arfolitixorin ISO-901; 6R-MTHF 临床三期 Isofol Medical Ab 直肠癌, 结肠癌, 骨肉瘤, 结直肠癌 详情

消息提示

请输入您的联系方式,再点击提交!

确定